A Phase 1 Study of ASP2138 in People With Pancreatic Cancer or Stomach or Gastroesophageal Junction Cancer That Makes Claudin (CLDN) 18.2


Full Title

A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression


Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.

ASP2138 binds to cancer cells that make CLDN 18.2 and helps the immune system fight cancer. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have pancreatic, gastric, or gastroesophageal junction cancer that has metastasized (spread).
  • Have completed prior treatments at least 3 weeks before getting ASP2138.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Wungki Park’s office at 646-888-4543.




Phase I (phase 1)


ClinicalTrials.gov ID